Table 2.
Demographics and distribution of patients among age classes, renal function, gender, race and sevoflurane use
| Covariate | Data set | n | Distribution of patients by class for each data set, n | Mean | SD | Minimum | Median | Maximum |
|---|---|---|---|---|---|---|---|---|
| Bodyweight (kg) | Pharmacokinetic model | 446 | NA | 72.5 | 19.2 | 9.60 | 74.5 | 139 |
| NMB with rocuronium | 59 | NA | 69.6 | 20.8 | 11.2 | 74.5 | 107 | |
| NMB with rocuronium + sugammadex reversal | 338 | NA | 73.0 | 19.3 | 9.60 | 75.0 | 139 | |
| Age (years) | Pharmacokinetic model | 446 | Infant/child/adolescent/elderly/old elderly*: 4/21/27/342/34/18 | 42.4 | 18.7 | 1 | 43 | 91 |
| NMB with rocuronium | 59 | Infant/child/adolescent/elderly/old elderly*: 1/4/6/48/0/0 | 35.4 | 16.8 | 1 | 36 | 64 | |
| NMB with rocuronium + sugammadex reversal | 338 | Infant/child/adolescent/elderly/old elderly*: 3/17/21/247/33/17 | 43.4 | 19.5 | 1 | 44 | 91 | |
| CLCR (ml min−1) | Pharmacokinetic model | 446 | Renal function, healthy/renally impaired†: 432/14 | 118 | 40.8 | 4.30 | 119 | 239 |
| NMB with rocuronium | 59 | Renal function, healthy/renally impaired†: 59/0 | 134 | 40.3 | 53.3 | 124 | 239 | |
| NMB with rocuronium + sugammadex reversal | 338 | Renal function, healthy/renally impaired†: 324/14 | 115 | 41.5 | 4.30 | 117 | 221 | |
| Gender | Pharmacokinetic model | 446 | Male/female: 289/157 | NA | NA | NA | NA | NA |
| NMB with rocuronium | 59 | Male/female: 43/16 | NA | NA | NA | NA | NA | |
| NMB with rocuronium + sugammadex reversal | 338 | Male/female: 212/126 | NA | NA | NA | NA | NA | |
| Race | Pharmacokinetic model | 446 | Non-Asian/Asian: 393‡/53 | NA | NA | NA | NA | NA |
| NMB with rocuronium | 59 | Non-Asian/Asian: 52/7 | NA | NA | NA | NA | NA | |
| NMB with rocuronium + sugammadex reversal | 338 | Non-Asian/Asian: 304§/34 | NA | NA | NA | NA | NA | |
| Sevoflurane use¶ | Pharmacokinetic model | NA | No/yes: NA | NA | NA | NA | NA | NA |
| NMB with rocuronium | 59 | No/yes: 45/14 | NA | NA | NA | NA | NA | |
| NMB with rocuronium + sugammadex reversal | 338 | No/yes: 235/103 | NA | NA | NA | N/A | NA |
Infant, 28 days to 23 months (but all were aged 1 year); child, 2–11 years; adolescent, 12–17 years; adult, 18–64 years; elderly, 65–74 years; and old elderly, ≥75 years.
Renal impairment defined as having a CLCR <30 ml min−1 (only applicable for the adult and elderly population; there were no renally impaired patients among the paediatric population).
Including 383 Caucasian, nine Afro-American and one Hispanic subject.
Including 295 Caucasian and nine Afro-American subjects.
Sevoflurane was included as a dichotomous covariate, being zero when no sevoflurane was administered.
Creatinine clearance (CLCR) for adult subjects (≥18 years) was calculated according to Cockcroft–Gault [37]. For paediatric subjects (<18 years), CLCR was based upon the formulae of Schwartz [38]. To obtain the uncorrected CLCR in paediatric subjects, the body surface area as calculated with the formula of Dubois and Dubois [39] was used. Age-matched height values taken from growth curves [44] were used for imputation of missing height values in paediatric patients. In case of a missing serum creatinine value, the formula: CLCR (ml min−1) = 183–1.34 × age (years) was used to impute CLCR for a particular adult subject; the formula: CLCR (ml min−1) = 53.8 + age1.75 (years) was used for missing serum CLCR in the paediatric population. These relationships were established upon fitting of age and CLCR values in the data set. There were no missing values for bodyweight and age. NA, not applicable; NMB, neuromuscular blockade.